Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
PETALUMA, Calif. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in Japan
PETALUMA, Calif. , Sept. 14, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018
Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. dermatology sales Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif. , July 25, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal first quarter 2018, ended June 30, 2017 , will be released after the U.S. markets close on August 8, 2017 .
View HTML
Toggle Summary CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
PETALUMA, Calif. , July 13, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sonoma Pharmaceuticals, Inc., please note that in the first paragraph of the release the company ticker symbols should be (NASDAQ:SNOA) (SNOAW), not (NASDAQ:OCLS) (OCLSW) as previously
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
Highest quarterly prescriptions filled in company's history
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact on Post-Procedure Treatment and Scar Prevention
PETALUMA, Calif. , June 28, 2017 (GLOBE NEWSWIRE) -- A distinguished panel of U.S. dermatologists and plastic surgeons explored current literature to establish the value of hypochlorous acid (HOCl) as both a pre- and post-procedure regime aimed at prevention of infection, reduction of inflammation
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars
PETALUMA, Calif. , June 20, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017
Product revenue for fourth quarter up 60% and for fiscal year 2017 up 48%, compared to last year, driven by growth in U.S. dermatology sales Cash position of $17.5 million ; management believes the company is more than fully funded to achieve EBITDA breakeven                      Conference Call
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2017 Financial Results and Conference Call
PETALUMA, Calif. , June 02, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal year and fourth quarter 2017, ended March 31, 2017 , will be released after the U.S. markets close on June 5, 2017 .
View HTML